Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL952400 | 1.00 | TBXAS1 (0.35) | TBXAS1ESR1TRPA1ALDH1A1 | |
| SCHEMBL6627009 | 0.94 | ALDH1A1 (0.31) | TBXAS1TRPA1ALDH1A1 | |
| SCHEMBL6627005 | 0.94 | ALDH1A1 (0.31) | TBXAS1TRPA1ALDH1A1 | |
| SCHEMBL3121426 | 0.86 | ALDH1A1 (0.33) | TRPA1ALDH1A1 | |
| SCHEMBL8425276 | 0.86 | ALDH1A1 (0.33) | TRPA1ALDH1A1 | |
| SCHEMBL3121422 | 0.86 | ALDH1A1 (0.33) | TRPA1ALDH1A1 | |
| SCHEMBL9099555 | 0.81 | CYP1A2 (0.38) | TBXAS1ALDH1A1 | |
| SCHEMBL8509399 | 0.81 | CYP1A2 (0.38) | TBXAS1ALDH1A1 | |
| SCHEMBL17337617 | 0.80 | DGKA (0.47) | TBXAS1ALDH1A1 | |
| SCHEMBL17337618 | 0.80 | DGKA (0.47) | TBXAS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637485-B2 | 5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase | SOUTHERN RESEARCH INSTITUTE (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2574616-A2 | 5'-substituted adenosynes, preparation thereof and use as inhibitors of s-adenosylmethionine decarboxylase. | Southern Research Institute (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-13 | — | — | US | disclosed |
| EP-2170057-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | Southern Research Institute (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009018541-A1 | 5'-SUBSTITUTED ADENOSYNES, PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | SOUTHERN RESEARCH INSTITUTE (US) | 2009-02-05 | — | — | WO | disclosed |
| EP-0889042-B1 | RADICICOL DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053990-A1 | Radicicol derivatives | KYOWA HAKKO KOGYO CO., LTD (JP) | 2004-03-18 | — | — | US | disclosed |
| US-6635662-B2 | A 2-oxime derivative; antitumor and -carcinogenic agents; immunosuppressents; osteoporosis; enzyme inhibitors of tyrosine kinase activity | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-21 | — | — | US | disclosed |
| US-6316491-B1 | INHIBITORS OF TYROSINE KINASE USED AS ANTITUMOR OR IMMUNOSUPPRESSION AGENTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-11-13 | — | — | US | disclosed |
| US-20010027208-A1 | Radicicol derivatives | INO YOJI (JP) | 2001-10-04 | — | — | US | disclosed |
| US-6239168-B1 | ANTITUMOR AGENTS, IMMUNOSUPPRESSANTS; TYROSINE KINASE INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0889042-A1 | RADICICOL DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053990-A1 | Radicicol derivatives | ROS1, LYN, SRC | TBXAS1 2656/4885ESR1 1350/4885TRPA1 2475/4885 |
| US-20110009354-A1 | 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE | AMD1, ADA, MTAP | TBXAS1 3035/4885ESR1 2570/4885TRPA1 4882/4885 |
| US-20010027208-A1 | Radicicol derivatives | ROS1, LYN, SRC | TBXAS1 2605/4885ESR1 1329/4885TRPA1 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.